Articles From: The Web Is Dying; Apps Are Killing It to UPDATE: 5 things that used to be free (but aren't anymore)


2014/11/16
By Christopher Mims The Web--that thin veneer of human-readable design on top of the machine babble that constitutes the Internet--is dying.
Sign-up for The Web Is Dying; Apps Are Killing It investment picks
2014/11/16
By Chelsey Dulaney And Paul Ziobro Nearing the one-year anniversary of Target Corp.'s massive and costly data breach, the company is looking to show that it has moved on.
Sign-up for Target Finishes Licking Its Wounds investment picks
-Only Rentrak Provides the Official Global Movie Results- LOS ANGELES , Nov.
Sign-up for Rentrak Announces Official Worldwide Box Office Results for Weekend of November 16, 2014 investment picks
2014/11/16
By Jonathan D.
Sign-up for Allergan, Actavis Near Deal -- 2nd Update investment picks
2014/11/16
By Daniel Gilbert In its effort to force a merger on Baker Hughes Inc. by replacing its board, Halliburton Co.
Sign-up for For Halliburton, Replacing Baker Board May Not Be Easy investment picks
Botox maker Allergan Inc. (AGN) and Irish pharmaceutical company Actavis PLC (ACT) are close to a friendly deal, which could be announced as early as Monday, the Wall Street Journal reported Sunday.
Sign-up for Allergan, Actavis near cash-and-stock deal: WSJ investment picks
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol.
Sign-up for AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting investment picks
2014/11/16
By Esther Fung SHANGHAI--Chinese property developer Evergrande Real Estate Group Ltd plans to invest around HK$950 million ($122.5 million) for a controlling stake in a Hong Kong-based magazine publisher, New Media Group Holdings--its latest foray in a new business line as the firm looks to diversify to cushion the risks from a weakened property market.
Sign-up for China's Evergrande Group Buys Publisher as Diversification Continues investment picks
Months of dedication and hard work in science, technology, engineering and mathematics (STEM) paid off tonight for three students named National Finalists in the Siemens Competition in Math, Science & Technology, the nation’s premier research competition for high school students.
Sign-up for Arizona and New Mexico High School Scientists Win Regional Siemens Competition at the University of Texas at Austin for Research on Intrinsically Disordered Proteins for Drug Discovery and Computational Models of Tree Growth investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trading in Monday's session are Tyson Foods Inc., Urban Outfitters Inc. and Agilent Technologies Inc. Tyson Foods (TSN) is projected to post fiscal fourth-quarter earnings of 76 cents a share, according to a consensus survey by FactSet.
Sign-up for UPDATE: Tyson, Urban Outfitters, Agilent earnings in focus investment picks
2014/11/16
By Wallace Witkowski, MarketWatch Home Depot, Lowe's, Target report results SAN FRANCISCO (MarketWatch) -- Earnings season wraps up this week as the last Dow component and most of the remaining S&P 500 companies report.
Sign-up for MARKET SNAPSHOT: Retailers Close Out Earnings Season investment picks
2014/11/16
By Wallace Witkowski, MarketWatch Home Depot, Lowe's, Target report results SAN FRANCISCO (MarketWatch) -- Earnings season wraps up this week as the last Dow component and most of the remaining S&P 500 companies report.
Sign-up for UPDATE: Retailers close out earnings season investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced preliminary results from a phase 1 investigator-sponsored trial (IST) evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma.
Sign-up for Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib investment picks
2014/11/15
By Ryan Dezember Martin Craighead's ascent to the upper levels of Baker Hughes Inc.'s management came as the oilfield-service company swallowed a rival to better compete with larger companies Halliburton Co.
Sign-up for Baker Hughes Lifer Defends His Firm investment picks
- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome - LA JOLLA, Calif.
Sign-up for Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting investment picks
2014/11/15
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch)--Shrek will not join forces with Transformers.
Sign-up for Hasbro-DreamWorks merger talks break down investment picks
2014/11/15
The second annual UnitedHealthcare IRONKIDS Tempe Fun Run raced around Tempe Beach Park today.
Sign-up for UnitedHealthcare Teams Up with IRONKIDS for First Ever Special Needs Course investment picks
2014/11/15
PetSmart, Inc. has partnered with the City of Slidell to bring a portable, pop-up dog park to Slidell.
Sign-up for PetSmart Unleashes Its One-of-a-Kind Pop-Up Park (P.U.P.) in Slidell investment picks
2014/11/15
Academy and GRAMMY Award winning artist Jennifer Hudson helps unwrap store and launch holiday season CHICAGO , Nov.
Sign-up for Verizon Wireless Unveils New Technology Destination on Chicago's Magnificent Mile investment picks
2014/11/15
The Estée Lauder brand today announced that it has signed Kendall Jenner, fashion’s new breakout star and social media sensation.
Sign-up for Estée Lauder Signs Model of the Moment and Social Media Phenomenon Kendall Jenner investment picks
2014/11/15
France won't kick off its planned asset sales by disposing of shares in Electricite de France SA, the French economy minister Emmanuel Macron said in a newspaper interview published Saturday.
Sign-up for France Won't Start Asset Sale With EDF Shares -- Report investment picks
2014/11/15
By Quentin Fottrell, MarketWatch Facebook (FB) Chief Executive Mark Zuckerberg dropped out of Harvard University, and yet became a billionaire before this 30th birthday.
Sign-up for UPDATE: 10 business schools that churn out billionaires investment picks
2014/11/15
By Quentin Fottrell, MarketWatch It's the fastest-growing online retail day of the year There's no need to worry about shoppers brandishing pepper spray this year: Black Friday is moving online.
Sign-up for UPDATE: Once a blood sport, Black Friday moves online investment picks
2014/11/15
By Quentin Fottrell, MarketWatch Once the purveyor of all things free and often the subject of copyright infringements due to consumers uploading videos, Google Inc.'s (GOOG) YouTube is starting a music subscription service for $9.99 a month, which is the same price as music-streaming services like Spotify.
Sign-up for UPDATE: 5 things that used to be free (but aren't anymore) investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: The Web Is Dying; Apps Are Killing It to UPDATE: 5 things that used to be free (but aren't anymore)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent